LiuYing
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (NCT05913570) | LiuYing | 2023-06-20 |
Track LiuYing automatically
Every clearance here is in the API, with alerts when new ones post.